Johnson & Johnson
Close on Nov 4, 2026Market cap $665.90BP/E 41.9Yield 1.86%
Johnson & Johnson SPRAVATO (esketamine) — U.S. sales by Year
SPRAVATO (esketamine) — U.S. sales ($M) ($M)
Johnson & Johnson SPRAVATO (esketamine) — U.S. sales: $1,485M in FY2025, up 59.8% from a year earlier.
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-11) ↗
Reported in Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | SPRAVATO (esketamine) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 1,485 | +59.8% | Form 10-K (filed 2026-02-11) ↗ |
| FY2024 | Dec 29, 2024 | 929 | +57.7% | Form 10-K (filed 2026-02-11) ↗ |
| FY2023 | Dec 31, 2023 | 589 | +79.6% | Form 10-K (filed 2026-02-11) ↗ |
| FY2022 | Jan 1, 2023 | 328 | – | Form 10-K (filed 2025-02-13) ↗ |
Breakdown
What makes up SPRAVATO (esketamine) — U.S. sales
Cite this data
StockData. (2026). Johnson & Johnson SPRAVATO (esketamine) — U.S. sales ($M), annual FY2022–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-spravato-us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?